New Antipsychotics 2025. This narrative review compares the pharmacology, clinical trial data and tolerability. Fda approved cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.

These novel antipsychotic medications have been hypothesized to produce clinical improvement through both dopaminergic and glutamatergeric mechanisms (see figure 1b). The food and drug administration.